Enable technology and product development. Just will accomplish its long-term mission of increasing global access to important biologics
through strategic technology and product partnerships.
“ We are proud of the significant work accomplished with our current partners to build a solid technology infrastructure at Just. We are now actively looking for product partnerships that leverage the strengths of Just for delivering meaningful therapeutics to a global marketplace.”
– Jim Thomas
BILL & MELINDA GATES FOUNDATION
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives.
Just is the recipient of two grants from the Bill & Melinda Gates Foundation. The first, to develop technology platforms to manufacture innovative and cost effective biologic medicines for diseases in low income markets. The second, to develop sequence optimized broadly neutralizing anti-HIV Antibodies for low cost manufacture and improved stability. The foundation is also an investor in Just.
Merck is an innovative, global healthcare leader that is committed to improving health and well-being around the world.
Just and Merck are in a Master Technology Development Agreement to jointly develop innovative technologies for lowering the cost of manufacturing biologics. Merck is also an equity investor in Just.
LabKey provides software solutions that help researchers overcome the data management and workflow challenges faced in today’s research environment.
Just is collaborating with LabKey to develop “LabKey Biologics,” a new and unique software product that helps biotechnology R&D teams produce more effective and affordable biotherapeutics by optimizing development processes. The new solution will enable preclinical research groups to accelerate lab workflows, automate project tracking, and gain immediate insight into molecules, processes and resources.
Hangzhou Just Biotherapeutics (Just China) is an affiliate company and shares the same mission to design and apply innovative technologies to dramatically expand global access to biotherapeutics.
Just and Just China are focusing their manufacturing, plant, facilities and engineering expertise on the design and build of the Just China facility in the Hangzhou Economic & Technology Development Area in China. Construction is expected to be completed and operational by early 2018. Just China will have access to Just’s dynamic tools for molecular design (Abacus™), process and product design (JP3®), and manufacturing plant design (J.Pod™), through services or license agreements with Just, to build an integrated platform for the accelerated development of low cost, high quality biotherapeutics.
G-CON Manufacturing designs, produces and installs prefabricated, autonomous cleanroom PODs(R). G-CON’s cleanroom POD® portfolio encompasses a variety of different dimensions and purposes, from laboratory environments to personalized medicine and production process platforms.
Just and G-CON are collaborating on Just China’s state of the art biologics facility, where G-CON’s prefabricated cleanroom PODs will be used to demonstrate Just’s J.Pod(™) technology – the fully equipped processing units capable of running highly intensified bioprocesses. J.Pods enable low cost, flexible and deployable manufacturing. By creating J.Pods™ we focus our molecular and process technologies into an efficient, integrated design that enables low cost, flexible manufacturing,”